Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman, MD, discusses findings from an ongoing phase Ib trial.
Recent Articles
Americans Owe $140 Billion in Medical Debt Sold to Collections Agencies
Americans owe $140 billion in medical debt that has been sold to collections agencies, according to research published in the Journal of the American...
FDA Supports Inclusion of Pregnant and Breastfeeding Women in Clinical Trials
Officials at the U.S. Food and Drug Administration (FDA) have announced their commitment to work with other regulators and industry to support the inclusion...
Cancer Death Rates Fell 1.4% More in Early Medicaid Expansion States
A new study published in the Journal of the National Cancer Institute (JNCI), cancer death rates declined more sharply in U.S. states that expanded...
Remembering Joel S. Bennett, Cancer Researchers Win Damon Runyon Physician-Scientist Training Awards, and more
Remembering Joel S. Bennett (1942 – 2021)
Joel S. Bennett, MD, died of pancreatic cancer on June 21, 2021, at the age of 78.Aside from...
Current Issue
August 2021 Volume 7 Issue 10
This issue explores hematologic conditions in athletes, blue top tube shortages, and more.